Brentuximab Vedotin in the First-Line Treatment of Patients With Classical Hodgkin Lymphoma Unsuitable for Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Results of a UK National Cancer Research Institute Phase II Study of Brentuximab Vedotin Using a Response-Adapted Design in the First-Line Treatment of Patients With Classical Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Comorbidity (BREVITY)
Br. J. Haematol 2020 Sep 14;[EPub Ahead of Print], A Gibb, SJ Pirrie, K Linton, V Warbey, K Paterson, AJ Davies, GP Collins, T Menne, P McKay, PA Fields, FM Miall, E Nagy, K Wheatley, R Reed, I Baricevic-Jones, S Barrington, J RadfordFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.